Is it pointed out that there is a risk of cancer and getting vaccinated can lead to weight loss? The "miracle drug" Smegglutide, which helps Musk lose 27 pounds, is carcinogenic
Last October, a netizen asked about Musk's secret to losing weight. Musk only answered two words: "dieting" and "wegovy".
Wegovy is an injectable form of "smeglutide", which is known as a weight loss miracle drug. It is said that just one injection per week can help people lose weight. Musk's "sales promotion" also quickly made this weight loss pill popular among many wealthy people. Musk said he lost a total of 30 pounds with the help of the drug.
According to recently released data, participants can lose an average of 44 pounds after taking similar oral medications. However, the European Medical Products Administration recently issued a notice stating that GLP-1 drugs, including products such as Wegovy, are at risk of developing thyroid cancer.
Weight loss drugs are accused of having a cancer risk
The stock price of pharmaceutical giants fell in response
GLP-1 is a hormone mainly produced by intestinal L cells and belongs to the category of intestinal proinsulin. The pharmacological mechanism of Smegglutide is to increase insulin secretion by stimulating the GLP-1 receptor and inhibit the secretion of glucagon, thereby achieving the goal of lowering blood sugar. Therefore, Smeglutide can not only help patients with type 2 diabetes control blood sugar, but also be used by people who are seeking efficiency to lose weight.
According to a report by Novo Nordisk to the market on the 22nd, the European Medical Products Administration has proposed a thyroid cancer safety signal for GLP-1 target drugs, which indicates that GLP-1 drugs have potential carcinogenic risks detected in experiments.
The official website of the European Medical Products Administration stated that experimental data found that after 1-3 years of using GLP-1 targeted drugs, the risk of thyroid cancer increased, and women had a higher risk than men.
Currently, in addition to Novo Nordisk, pharmaceutical companies such as AstraZeneca, Sanofi, and Lilly are also producing large quantities of GLP-1 drugs.
Lars Otto, Director of Media Relations at Novo Nordisk, said, "Novo Nordisk understands the safety requirements of the European Medical Products Administration and will conduct a comprehensive evaluation of all relevant data. We take the issue of drug side effects very seriously."
At present, Novo Nordisk has obtained market approval for three Smegglutide drugs under the US FDA, namely Ozempic, Wegovy, and Rybelsus. After the news was released, Novo Nordisk, which has performed well in stock prices since the beginning of this year, immediately suffered a heavy setback, with its stock price falling by more than 2%. According to statistics, the sales of three Smegglutide drugs accounted for nearly 44% of Novo Nordisk's total sales in 2022.
Musk revealed a weight loss of 27 pounds
Claiming to lose weight with just one injection per week
Last October, many netizens noticed that Musk was rapidly losing weight and his body shape was improving at an astonishing rate. Just two months ago, photos of Musk's loose body and pale skin during his vacation in Greece were leaked, and netizens jokingly referred to him as "matching the size of a little plum". A netizen asked on Twitter, "Why do you look so healthy and strong? Have you been exercising or eating healthily?" Musk replied, "Dieting, and Wegovy.".
Afterwards, when answering questions from the Silicon Valley Tesla Car Club, Musk stated that he had lost a full 30 pounds. Former Twitter CEO Jack Dorsey responded on behalf of Musk, stating that in addition to taking Wegovy medication, Musk also adopted an "intermittent fasting" weight loss method. When Musk dined, the food on the plate was mainly fish, chicken, and steak, as well as a large amount of green vegetables.
According to the official Wegovy product website, the product only needs to be injected once a week and is suitable for obese individuals over 12 years old and overweight adults. However, the official website emphasizes that the injection of Wegovy must strictly follow the doctor's advice, and patients need to communicate in detail with the doctor about their kidney, cardiovascular, blood sugar, and other health conditions before use. The official website also warns that this product is not suitable for people with thyroid cancer, and it is not recommended to mix it with other over-the-counter weight loss drugs.
According to media reports, Wegovy was originally very popular in wealthy circles such as Silicon Valley, Wall Street, and Hollywood, but became even more popular after Musk's "sales promotion". Novo Nordisk stated that they were not aware that Musk was taking Wegovy until Musk announced it himself.
High selling prices on domestic e-commerce platforms
Pharmaceutical company claims to develop oral tablets
In 2021, Novo Nordisk's Smeaglutide injection "Novotel" was approved for marketing in China and is currently only used to improve blood sugar control in patients with type 2 diabetes. In December 2022, Novotel was included in the national medical insurance directory. On June 3rd of this year, the official website of the Drug Approval Center of the National Medical Products Administration showed that the application for listing of Novotel New Indications has been officially accepted.
At present, in China, due to some weight loss enthusiasts rushing to purchase Novotel, the retail price of the drug on e-commerce platforms is higher than the selling price through hospital channels. Red Star News reporters have searched multiple e-commerce platforms in China and found that a 1.5ml bottle of Novotel is generally priced above 620 yuan, while a 3ml bottle is priced above 1100 yuan. A price catalog released by a public hospital shows that the same specifications of Novotel are priced at 478.8 yuan/unit and 813.96 yuan/unit, respectively.
The crazy scramble of dieters has led to frequent stock outs of drugs originally designed for diabetes patients since last year. A netizen in Hangzhou posted a post last year saying, "At the beginning of each month, he called the pharmacy of each major hospital to ask if there was any medicine, and each hospital said no, and asked the doctor that he had been given away at his own expense." In April this year, a netizen in Chongqing posted a post asking: "Which hospital in Chongqing has Smeaglutide, and patients with diabetes can't get medicine." Medical staff reminded that when buying medicine in scalpers, e-commerce platforms and other channels, you should be careful to identify the authenticity and guard against security risks.
Despite being issued a safety signal by the European Medical Products Administration, Novo Nordisk continues to promote the development of smeglutide. There are reports that the company is developing an oral form of smeglutide medication, which is convenient for patients who want to use Wegovy and Novotel but are afraid of injections.
At present, this oral tablet has entered the third phase of clinical trials, and the results of the randomized double-blind controlled trial have been good. According to the data released by the American diabetes Association on the 25th of this month, 86% of the patients in the experimental group completed the 68 week experimental process, and they lost 44 pounds on average, accounting for 17.4% of the original weight base. As a comparison, the control group members who took the placebo only lost an average of 1.8% of their weight.